JP2015523969A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015523969A5 JP2015523969A5 JP2015514193A JP2015514193A JP2015523969A5 JP 2015523969 A5 JP2015523969 A5 JP 2015523969A5 JP 2015514193 A JP2015514193 A JP 2015514193A JP 2015514193 A JP2015514193 A JP 2015514193A JP 2015523969 A5 JP2015523969 A5 JP 2015523969A5
- Authority
- JP
- Japan
- Prior art keywords
- lipid
- nanoparticle
- nanoparticles
- lipid nanoparticle
- lipid nanoparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 claims 26
- 239000002105 nanoparticle Substances 0.000 claims 18
- 229920000642 polymer Polymers 0.000 claims 6
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 claims 4
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- 239000002202 Polyethylene glycol Substances 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- LSHROXHEILXKHM-UHFFFAOYSA-N n'-[2-[2-[2-(2-aminoethylamino)ethylamino]ethylamino]ethyl]ethane-1,2-diamine Chemical compound NCCNCCNCCNCCNCCN LSHROXHEILXKHM-UHFFFAOYSA-N 0.000 claims 3
- 229920001223 polyethylene glycol Polymers 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- 229920002873 Polyethylenimine Polymers 0.000 claims 2
- 239000001961 anticonvulsive agent Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000007330 LDL Lipoproteins Human genes 0.000 claims 1
- 108010007622 LDL Lipoproteins Proteins 0.000 claims 1
- 229940123247 Neurotransmitter antagonist Drugs 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
- 230000000507 anthelmentic effect Effects 0.000 claims 1
- -1 anthelmintic Substances 0.000 claims 1
- 230000000844 anti-bacterial effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000003178 anti-diabetic effect Effects 0.000 claims 1
- 230000003556 anti-epileptic effect Effects 0.000 claims 1
- 230000000843 anti-fungal effect Effects 0.000 claims 1
- 230000001384 anti-glaucoma Effects 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 230000002141 anti-parasite Effects 0.000 claims 1
- 230000003356 anti-rheumatic effect Effects 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 229940124344 antianaemic agent Drugs 0.000 claims 1
- 239000003173 antianemic agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 238000011026 diafiltration Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229940014144 folate Drugs 0.000 claims 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000003667 hormone antagonist Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000004957 immunoregulator effect Effects 0.000 claims 1
- 239000003589 local anesthetic agent Substances 0.000 claims 1
- 229960005015 local anesthetics Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000003533 narcotic effect Effects 0.000 claims 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000001624 sedative effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 150000003722 vitamin derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261650729P | 2012-05-23 | 2012-05-23 | |
| US61/650,729 | 2012-05-23 | ||
| US201361784892P | 2013-03-14 | 2013-03-14 | |
| US61/784,892 | 2013-03-14 | ||
| PCT/US2013/042461 WO2013177421A2 (en) | 2012-05-23 | 2013-05-23 | Lipid-coated albumin nanoparticle compositions and methods of making and method of using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015523969A JP2015523969A (ja) | 2015-08-20 |
| JP2015523969A5 true JP2015523969A5 (https=) | 2016-03-17 |
| JP6228191B2 JP6228191B2 (ja) | 2017-11-08 |
Family
ID=48539454
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514189A Expired - Fee Related JP6220389B2 (ja) | 2012-05-23 | 2013-05-23 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
| JP2015514193A Active JP6228191B2 (ja) | 2012-05-23 | 2013-05-23 | 脂質コートされたアルブミンナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 |
| JP2015514192A Pending JP2015525209A (ja) | 2012-05-23 | 2013-05-23 | 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 |
| JP2017191221A Pending JP2018002727A (ja) | 2012-05-23 | 2017-09-29 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514189A Expired - Fee Related JP6220389B2 (ja) | 2012-05-23 | 2013-05-23 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015514192A Pending JP2015525209A (ja) | 2012-05-23 | 2013-05-23 | 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 |
| JP2017191221A Pending JP2018002727A (ja) | 2012-05-23 | 2017-09-29 | アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US9750819B2 (https=) |
| EP (3) | EP2852380A4 (https=) |
| JP (4) | JP6220389B2 (https=) |
| KR (3) | KR20150032945A (https=) |
| CN (3) | CN104428005B (https=) |
| AU (4) | AU2013266238B2 (https=) |
| BR (2) | BR112014027834A2 (https=) |
| CA (3) | CA2874490C (https=) |
| MX (3) | MX353567B (https=) |
| WO (3) | WO2013177421A2 (https=) |
Families Citing this family (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201803982TA (en) | 2008-05-16 | 2018-07-30 | Taiga Biotechnologies Inc | Antibodies and processes for preparing the same |
| DK3339321T3 (da) | 2008-08-28 | 2021-06-21 | Taiga Biotechnologies Inc | Modulatorer af myc, fremgangsmåder til anvendelse af samme og fremgangsmåder til at identificere stoffer der modulerer myc |
| WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2625189B1 (en) | 2010-10-01 | 2018-06-27 | ModernaTX, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| DE19216461T1 (de) | 2011-10-03 | 2021-10-07 | Modernatx, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013151665A2 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins associated with human disease |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| EP2852380A4 (en) * | 2012-05-23 | 2016-01-20 | Univ Ohio State | LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF |
| US9789135B2 (en) | 2012-07-20 | 2017-10-17 | Taiga Biotechnologies, Inc. | Enhanced reconstitution and autoreconstitution of the hematopoietic compartment |
| PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
| US10272115B2 (en) | 2013-03-11 | 2019-04-30 | Taiga Biotechnologies, Inc. | Production and use of red blood cells |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2014178152A1 (ja) | 2013-04-30 | 2014-11-06 | Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 | 局所投与用リポソームおよびその用途 |
| WO2014205000A1 (en) * | 2013-06-17 | 2014-12-24 | University Of North Carolina At Chapel Hill | Polymer coated particles and methods thereof |
| EP3024936B1 (en) | 2013-07-25 | 2019-09-04 | Exicure, Inc. | Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| US9833416B2 (en) * | 2014-04-04 | 2017-12-05 | Ohio State Innovation Foundation | Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same |
| WO2015175965A1 (en) * | 2014-05-15 | 2015-11-19 | The Research Foundation For Suny | Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof |
| TR201908550T4 (tr) | 2014-06-04 | 2019-07-22 | Exicure Inc | Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi. |
| WO2016028940A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| AU2015337909B2 (en) | 2014-10-30 | 2018-12-13 | Delta-Fly Pharma, Inc. | New production method of lipoplex for local administration and antitumor drug using lipoplex |
| US11213593B2 (en) | 2014-11-21 | 2022-01-04 | Northwestern University | Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates |
| CA2973702A1 (en) * | 2015-01-14 | 2016-07-21 | Exicure, Inc. | Nucleic acid nanostructures with core motifs |
| US20160287152A1 (en) * | 2015-03-30 | 2016-10-06 | Verily Life Sciences Llc | Functionalized Nanoparticles, Methods and In Vivo Diagnostic System |
| EP4353257A3 (en) | 2015-04-13 | 2024-08-07 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| KR20190118688A (ko) * | 2015-06-05 | 2019-10-18 | 미라젠 세러퓨틱스 인코포레이티드 | 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제 |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| CN105288647B (zh) * | 2015-10-10 | 2018-05-25 | 中国药科大学 | 功能化白蛋白及其纳米制剂的制备方法 |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
| CN107951862B (zh) * | 2016-10-17 | 2021-03-12 | 南京绿叶制药有限公司 | 一种抑制bcl-2的反义寡聚核酸的脂质纳米粒及其制备方法 |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| EP3548425B1 (en) * | 2016-12-02 | 2023-03-29 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
| WO2018107061A1 (en) * | 2016-12-09 | 2018-06-14 | Board Of Regents, The University Of Texas System | Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics |
| CN110225770B (zh) | 2016-12-14 | 2022-04-26 | 杨森生物科技公司 | 结合cd8a的纤连蛋白iii型结构域 |
| EP3554535A4 (en) | 2016-12-14 | 2020-10-21 | Janssen Biotech, Inc. | PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS |
| EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| CN109996569B (zh) * | 2016-12-22 | 2022-05-03 | 百多力股份公司 | 用于医疗装置的药物释放涂层及其制备方法 |
| US20180179577A1 (en) * | 2016-12-22 | 2018-06-28 | Jiaming HU | Lipid-polymer Hybrid Nanoparticle Biochip and Application Thereof |
| WO2018124423A1 (ko) * | 2016-12-30 | 2018-07-05 | 주식회사 삼양바이오팜 | 플라스미드 디엔에이 전달용 고분자 나노입자 조성물 및 그의 제조방법 |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| EP4186888B1 (en) | 2017-03-15 | 2025-11-26 | ModernaTX, Inc. | Compound and compositions for intracellular delivery of therapeutic agents |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| CN107184552B (zh) * | 2017-06-07 | 2021-03-30 | 东华大学 | 一种半乳糖化聚乙烯亚胺修饰的载药醇质体的制备方法 |
| WO2018232120A1 (en) | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| JP7231147B2 (ja) * | 2017-06-29 | 2023-03-01 | 国立大学法人東海国立大学機構 | Ｒｎａ導入試薬及びその利用 |
| CN111133314B (zh) * | 2017-07-18 | 2025-03-04 | 阿维塔斯有限公司 | 使用连续流动的流体系统进行跨细胞膜的有效装载的传递 |
| US10149898B2 (en) | 2017-08-03 | 2018-12-11 | Taiga Biotechnologies, Inc. | Methods and compositions for the treatment of melanoma |
| WO2019040516A1 (en) * | 2017-08-22 | 2019-02-28 | Rubius Therapeutics, Inc. | METHODS AND COMPOSITIONS OF LIPID NANOPARTICLES FOR THE PRODUCTION OF MODIFIED ERYTHROID CELLS |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| CN107982537A (zh) * | 2017-11-17 | 2018-05-04 | 厦门大学 | 针对microRNA-155的治疗性药物及其应用 |
| KR102245539B1 (ko) * | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
| EP3789043A4 (en) * | 2018-03-29 | 2022-08-03 | Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences | Extraction of plant source "medicinal soup" and manual preparation of "herbal medicine" and related products |
| CN112312918A (zh) * | 2018-04-18 | 2021-02-02 | 奥依信生物技术公司 | 促融合脂质纳米粒和制备其的方法以及其用于靶细胞特异性产生治疗蛋白和治疗与靶细胞有关的疾病、病况或障碍的用途 |
| US20210219550A1 (en) * | 2018-05-15 | 2021-07-22 | Flagship Pioneering Innovations Vi, Llc | Pest control compositions and uses thereof |
| CN112423738B (zh) * | 2018-06-01 | 2023-06-20 | 西江大学校产学协力团 | 通过利用脂质的表面改性提升细胞内摄取效率的纳米粒子复合体及其制造方法 |
| US10987428B2 (en) * | 2018-06-01 | 2021-04-27 | City Of Hope | Phosphorothioate-conjugated miRNAs and methods of using the same |
| CN108743962B (zh) * | 2018-06-19 | 2021-07-02 | 东华大学 | 一种基于荧光碳点修饰的树状大分子的双载药靶向纳米平台的制备方法 |
| US12357580B2 (en) | 2018-06-19 | 2025-07-15 | The Board Of Regents Of The University Of Texas System | Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids |
| WO2020051223A1 (en) | 2018-09-04 | 2020-03-12 | The Board Of Regents Of The University Of Texas System | Compositions and methods for organ specific delivery of nucleic acids |
| EP3846857A4 (en) * | 2018-09-04 | 2022-10-12 | The Board Of Regents Of The University Of Texas System | COMPOSITIONS AND METHODS FOR ORGAN-SPECIFIC DELIVERY OF NUCLEIC ACIDS |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| JP2022516318A (ja) * | 2019-01-04 | 2022-02-25 | オンコラス， インコーポレイテッド | カプセル化ポリヌクレオチド及び使用方法 |
| CN113874033A (zh) | 2019-04-08 | 2021-12-31 | 泰加生物工艺学公司 | 用于冷冻保存免疫细胞的组合物和方法 |
| EP3969041A4 (en) | 2019-05-14 | 2023-05-10 | Taiga Biotechnologies, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF T-CELL DEPLETION |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| CN119119240A (zh) | 2019-10-14 | 2024-12-13 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076543A1 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| CN115778904B (zh) * | 2019-10-29 | 2025-03-28 | 珠海丽凡达生物技术有限公司 | 一种用于体外转染和体内递送mRNA的制剂 |
| KR102198736B1 (ko) | 2020-01-15 | 2021-01-05 | 이화여자대학교 산학협력단 | 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도 |
| WO2021167703A1 (en) * | 2020-02-19 | 2021-08-26 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
| ES3054438T3 (en) | 2020-07-16 | 2026-02-03 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| EP4196128A4 (en) * | 2020-08-14 | 2024-06-12 | Arcturus Therapeutics, Inc. | METHOD FOR FREEZE DILIZATION OF LIPID NANOPARTICLES |
| WO2022192674A1 (en) * | 2021-03-11 | 2022-09-15 | The Trustees Of The University Of Pennsylvania | Targeted therapeutic lipid nanoparticles and methods of use |
| EP4323008A4 (en) | 2021-04-14 | 2026-02-25 | Aro Biotherapeutics Company | FN3-ARNSI DOMAIN CONJUGATES AND THEIR USES |
| CA3214552A1 (en) | 2021-04-14 | 2022-10-20 | Russell C. Addis | Cd71 binding fibronectin type iii domains |
| KR20250010108A (ko) | 2021-04-20 | 2025-01-20 | 비온드 바이오로직스 엘티디 | 세포내 전달 조성물 |
| EP4419112A4 (en) * | 2021-10-22 | 2025-08-27 | Ohio State Innovation Foundation | IMMUNOTHERAPY FOR CANCER TREATMENT |
| JP7818700B2 (ja) * | 2021-11-03 | 2026-02-20 | ビオンド バイオロジクス リミテッド | 細胞内送達組成物 |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| CN114306369B (zh) * | 2021-12-23 | 2023-12-26 | 北京悦康科创医药科技股份有限公司 | 一种硫代寡核苷酸注射液及其制备方法 |
| CA3246723A1 (en) * | 2022-03-30 | 2023-10-05 | The Johns Hopkins University | Lipid nanoparticle compositions for the delivery of plasma DNA to the liver and their preparation methods |
| WO2024044370A1 (en) * | 2022-08-25 | 2024-02-29 | Ohio State Innovation Foundation | Compositions and methods for the delivery of active agents including nucleic acids |
| US20260069713A1 (en) * | 2022-08-29 | 2026-03-12 | Vivasor, Inc. | Lipid-Coated Nanoparticles |
| WO2024136219A1 (ko) * | 2022-12-19 | 2024-06-27 | 주식회사 포스테라헬스사이언스 | 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법 |
| AU2024241934A1 (en) * | 2023-03-31 | 2025-10-23 | The Whiteoak Group, Inc. | Liposomal compositions of archexin |
| WO2025034965A1 (en) * | 2023-08-09 | 2025-02-13 | Board Of Regents, The University Of Texas System | Targeted therapeutic delivery of lipid nanoparticles |
| CN121752254A (zh) | 2023-08-11 | 2026-03-27 | 浙江海昶生物医药股份有限公司 | 一种具有靶向性的脂质组合物及其制备方法 |
| TWI880568B (zh) * | 2024-01-04 | 2025-04-11 | 訊聯生物科技股份有限公司 | 包含生物巨分子及奈米載體之組合物、包含其的醫藥組成物及其用途 |
| WO2025171027A1 (en) * | 2024-02-05 | 2025-08-14 | University Of Rhode Island Board Of Trustees | Phlip ®-lnp for targeted intracellular delivery of nucleic acid therapeutics |
| US12553050B2 (en) | 2024-03-22 | 2026-02-17 | Takeda Pharmaceutical Company Limited | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression |
| WO2025221397A1 (en) * | 2024-04-17 | 2025-10-23 | University Of Connecticut | Albumin nanoparticles for efficient vaccine delivery |
| KR20250157196A (ko) * | 2024-04-26 | 2025-11-04 | 한국과학기술원 | 핵산 분자의 흡입 전달용 지질 나노복합체 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US590877A (en) * | 1897-09-28 | Danger-signal for railway-crossings | ||
| US2003203A (en) * | 1933-05-15 | 1935-05-28 | Kim Young Wo | Game |
| US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
| ES2105262T3 (es) | 1992-05-18 | 1997-10-16 | Minnesota Mining & Mfg | Dispositivo de suministro de farmaco a traves de las mucosas. |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US20020022264A1 (en) * | 1995-05-26 | 2002-02-21 | Sullivan Sean M. | Delivery vehicles comprising stable lipid/nucleic acid complexes |
| US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| US6248720B1 (en) * | 1996-07-03 | 2001-06-19 | Brown University Research Foundation | Method for gene therapy using nucleic acid loaded polymeric microparticles |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| JP2002508765A (ja) | 1997-06-23 | 2002-03-19 | アルザ コーポレイション | リポソーム被包ポリヌクレオチド組成物および方法 |
| US6395253B2 (en) * | 1998-04-23 | 2002-05-28 | The Regents Of The University Of Michigan | Microspheres containing condensed polyanionic bioactive agents and methods for their production |
| WO2000076497A1 (en) | 1999-06-14 | 2000-12-21 | Cancer Research Ventures Limited | Cancer therapy |
| EP1212085B1 (en) * | 1999-08-27 | 2007-10-31 | INEX Pharmaceuticals Corp. | Compositions for stimulating cytokine secretion and inducing an immune response |
| US7060291B1 (en) * | 1999-11-24 | 2006-06-13 | Transave, Inc. | Modular targeted liposomal delivery system |
| AU2001255260A1 (en) | 2000-04-07 | 2001-10-23 | Baylor College Of Medicine | Macroaggregated protein conjugates as oral genetic immunization delivery agents |
| US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| JP2004535388A (ja) * | 2001-04-30 | 2004-11-25 | ターゲティッド ジェネティクス コーポレイション | 脂質含有薬物送達複合体およびそれらの生成方法 |
| RU2294192C2 (ru) | 2001-05-30 | 2007-02-27 | Дзе Скриппс Рисерч Инститьют | Система доставки нуклеиновых кислот |
| JP2003088371A (ja) * | 2001-09-04 | 2003-03-25 | Mitsubishi Pharma Corp | 遺伝子導入用組成物 |
| KR100484371B1 (ko) | 2001-10-25 | 2005-04-20 | 가부시키가이샤 아텍스 | 히터선부착 시트체의 제조방법 |
| EP1441763A2 (en) * | 2001-11-07 | 2004-08-04 | Inex Pharmaceuticals Corp. | Mucosal adjuvants comprising an oligonucleotide and a cationic lipid |
| US7678386B2 (en) | 2002-07-15 | 2010-03-16 | Board Of Regents The University Of Texas | Liposomes coated with selected antibodies that bind to aminophospholipids |
| CN100558740C (zh) * | 2002-08-16 | 2009-11-11 | 雷克珊公司 | 反义寡核苷酸用于抑制Akt-1表达的用途 |
| US20040208921A1 (en) * | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| JP4546454B2 (ja) * | 2003-01-28 | 2010-09-15 | レクサーン・コーポレイション | Ｈｉｆ−１発現を抑制するアンチセンスオリゴヌクレオチド |
| CN100471862C (zh) * | 2003-01-31 | 2009-03-25 | 雷克珊公司 | 抑制hif-1表达的反义寡核苷酸 |
| EP1664316B1 (en) * | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| KR100638041B1 (ko) | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| JP2006111591A (ja) | 2004-10-15 | 2006-04-27 | Anges Mg Inc | 核酸医薬を標的特異的に細胞内送達するための製剤 |
| JP2006298780A (ja) * | 2005-04-15 | 2006-11-02 | Tohoku Univ | Ｈｇｆ遺伝子と粗大凝集アルブミン−ポリエチレンイミン（ｍａａ−ｐｅｉ）との複合体 |
| US20070087045A1 (en) * | 2005-10-14 | 2007-04-19 | Industrial Technology Research Institute | Lipid carrier and method of preparing the same |
| TW200800235A (en) * | 2005-10-18 | 2008-01-01 | Otsuka Pharma Co Ltd | Carrier composition for nucleic acid transport |
| CN101346393B (zh) * | 2005-11-02 | 2015-07-22 | 普洛体维生物治疗公司 | 修饰的siRNA分子及其应用 |
| US8067380B2 (en) | 2005-12-19 | 2011-11-29 | Industrial Technology Research Institute | Glutathione-based delivery system |
| GB2450475A (en) | 2007-06-12 | 2008-12-31 | Univ Nottingham Trent | Antimicrobial polymer nanocomposite |
| WO2009026328A2 (en) * | 2007-08-21 | 2009-02-26 | Immune Disease Institute, Inc. | Methods of delivery of agents to leukocytes and endothelial cells |
| PL208054B1 (pl) * | 2007-09-06 | 2011-03-31 | Akademia Medyczna Im Piastow Śląskich We Wrocławiu | Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie |
| EP2217221B1 (en) * | 2007-10-17 | 2018-06-27 | Korea Advanced Institute of Science and Technology | Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same |
| AU2008325122A1 (en) * | 2007-11-09 | 2009-05-14 | Northeastern University | Self-assembling micelle-like nanoparticles for systemic gene delivery |
| US8916531B2 (en) * | 2007-11-20 | 2014-12-23 | Isis Pharmaceuticals, Inc. | Modulation of CD40 expression |
| CA2710983A1 (en) | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
| US8445021B2 (en) | 2008-04-04 | 2013-05-21 | The Regents Of The University Of California | Functionalized magnetic nanoparticles and methods of use thereof |
| US8222220B2 (en) | 2008-05-13 | 2012-07-17 | George Mason Intellectual Properties, Inc. | Nanogenomics for medicine: siRNA engineering |
| CA2724408A1 (en) * | 2008-05-19 | 2009-11-26 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
| US20090312402A1 (en) * | 2008-05-20 | 2009-12-17 | Contag Christopher H | Encapsulated nanoparticles for drug delivery |
| EP2321414B1 (en) * | 2008-07-25 | 2018-01-10 | Alnylam Pharmaceuticals, Inc. | Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
| WO2010014595A2 (en) | 2008-07-31 | 2010-02-04 | The Ohio State University Research Foundation | Methods and compositions for delivering therapeutic agents in the treatment of b-cell related disorders |
| US20110256059A1 (en) * | 2008-10-28 | 2011-10-20 | Universidade De Santiago De Compostela | Nanoparticulate systems prepared from anionic polymers |
| US8722082B2 (en) | 2008-11-10 | 2014-05-13 | Tekmira Pharmaceuticals Corporation | Lipids and compositions for the delivery of therapeutics |
| EP2210589B1 (en) | 2009-01-22 | 2015-05-06 | Ludwig-Maximilians-Universität München | Vesicular phospholipid gels comprising proteinaceous substances |
| ES2351756B1 (es) | 2009-07-28 | 2011-10-05 | Universidad Del Pais Vasco | Nanopartículas lipídicas para terapia génica. |
| AU2010321555B2 (en) * | 2009-11-23 | 2015-10-15 | The Ohio State University | Materials and methods useful for affecting tumor cell growth, migration and invasion |
| EP2553019A1 (en) * | 2010-03-26 | 2013-02-06 | Mersana Therapeutics, Inc. | Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof |
| AU2011232669B2 (en) * | 2010-03-26 | 2016-08-25 | The Ohio State University | Materials and methods related to modulation of mismatch repair and genomic stability by miR-155 |
| WO2011133504A2 (en) | 2010-04-20 | 2011-10-27 | University Of Florida Research Foundation, Inc. | Nanozymes, methods of making nanozymes, and methods of using nanozymes |
| WO2011133868A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | Conformationally restricted dinucleotide monomers and oligonucleotides |
| US20110319473A1 (en) * | 2010-06-29 | 2011-12-29 | Surmodics, Inc. | Compositions and methods for enhancement of nucleic acid delivery |
| US8691750B2 (en) * | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| CN102552105B (zh) * | 2011-10-17 | 2014-04-02 | 复旦大学 | 一种级联脑部靶向药物递送系统及其制备方法和用途 |
| EP2852380A4 (en) * | 2012-05-23 | 2016-01-20 | Univ Ohio State | LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF |
-
2013
- 2013-05-23 EP EP13794381.7A patent/EP2852380A4/en not_active Withdrawn
- 2013-05-23 CN CN201380026005.5A patent/CN104428005B/zh active Active
- 2013-05-23 KR KR1020147036015A patent/KR20150032945A/ko not_active Withdrawn
- 2013-05-23 WO PCT/US2013/042461 patent/WO2013177421A2/en not_active Ceased
- 2013-05-23 CA CA2874490A patent/CA2874490C/en active Active
- 2013-05-23 MX MX2014014251A patent/MX353567B/es active IP Right Grant
- 2013-05-23 EP EP13726404.0A patent/EP2852415A1/en not_active Withdrawn
- 2013-05-23 AU AU2013266238A patent/AU2013266238B2/en active Active
- 2013-05-23 JP JP2015514189A patent/JP6220389B2/ja not_active Expired - Fee Related
- 2013-05-23 AU AU2013266236A patent/AU2013266236A1/en not_active Abandoned
- 2013-05-23 US US14/403,313 patent/US9750819B2/en active Active
- 2013-05-23 US US14/403,315 patent/US20160015824A1/en not_active Abandoned
- 2013-05-23 WO PCT/US2013/042454 patent/WO2013177415A1/en not_active Ceased
- 2013-05-23 EP EP13794027.6A patent/EP2852381B1/en active Active
- 2013-05-23 MX MX2014014196A patent/MX2014014196A/es unknown
- 2013-05-23 CA CA2874495A patent/CA2874495A1/en not_active Abandoned
- 2013-05-23 BR BR112014027834A patent/BR112014027834A2/pt not_active Application Discontinuation
- 2013-05-23 KR KR1020147032915A patent/KR20150020180A/ko not_active Ceased
- 2013-05-23 MX MX2018000744A patent/MX384803B/es unknown
- 2013-05-23 JP JP2015514193A patent/JP6228191B2/ja active Active
- 2013-05-23 CN CN201380033174.1A patent/CN105163721B/zh active Active
- 2013-05-23 WO PCT/US2013/042458 patent/WO2013177419A2/en not_active Ceased
- 2013-05-23 BR BR112014029247A patent/BR112014029247A2/pt not_active IP Right Cessation
- 2013-05-23 KR KR1020147036014A patent/KR102169891B1/ko active Active
- 2013-05-23 CA CA2871477A patent/CA2871477A1/en not_active Abandoned
- 2013-05-23 US US13/900,969 patent/US10307490B2/en active Active
- 2013-05-23 JP JP2015514192A patent/JP2015525209A/ja active Pending
- 2013-05-23 CN CN201380033165.2A patent/CN104582691A/zh active Pending
- 2013-05-23 AU AU2013266232A patent/AU2013266232B2/en not_active Ceased
-
2017
- 2017-08-29 US US15/689,667 patent/US20180021447A1/en not_active Abandoned
- 2017-09-29 JP JP2017191221A patent/JP2018002727A/ja active Pending
- 2017-10-09 AU AU2017245294A patent/AU2017245294B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015523969A5 (https=) | ||
| Ge et al. | Fluorinated α-helical polypeptides synchronize mucus permeation and cell penetration toward highly efficient pulmonary siRNA delivery against acute lung injury | |
| Yadav et al. | Advances in delivery of chemotherapeutic agents for cancer treatment | |
| Prabhu et al. | Polymeric nanoparticles for targeted treatment in oncology: current insights | |
| Zhao et al. | Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents | |
| Yousefpour Marzbali et al. | Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review | |
| JP2019524885A5 (https=) | ||
| Vllasaliu et al. | PEGylated nanomedicines: recent progress and remaining concerns | |
| Fox et al. | Synthesis and in vivo antitumor efficacy of PEGylated poly (l-lysine) dendrimer− camptothecin conjugates | |
| Kibria et al. | Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery | |
| Garbuzenko et al. | Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention | |
| Sah et al. | Concepts and practices used to develop functional PLGA-based nanoparticulate systems | |
| Xu et al. | Bio-inspired supramolecular hybrid dendrimers self-assembled from low-generation peptide dendrons for highly efficient gene delivery and biological tracking | |
| Tian et al. | Amphiphilic polymeric micelles as the nanocarrier for peroral delivery of poorly soluble anticancer drugs | |
| CN102858367B (zh) | 抗原或药物递送复合物 | |
| Zou et al. | Nanocarriers with tunable surface properties to unblock bottlenecks in systemic drug and gene delivery | |
| JP2017526744A5 (https=) | ||
| Sun et al. | Polymers in the co-delivery of siRNA and anticancer drugs for the treatment of drug-resistant cancers | |
| JP2019524802A5 (https=) | ||
| Mehrabadi et al. | Dendritic and lipid-based carriers for gene/siRNA delivery (a review) | |
| JP2015519346A5 (https=) | ||
| KR20110112305A (ko) | 베시클 제제 | |
| Játiva et al. | Use of nanoparticles for glioblastoma treatment: a new approach | |
| JP7803714B2 (ja) | 複数のリガンドで機能化されたポリマーソーム | |
| US20160213788A1 (en) | Active targeting antitumor drug and preparation method therefor |